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Background-—Adjuvant cancer treatments have been shown to decrease cardiac function. In addition to changes in cardiovascular
risk, there are several additional functional consequences including decreases in exercise capacity and increased incidence of
cancer-related fatigue. However, the effects of adjuvant cancer treatment on peripheral vascular function during exercise in cancer
survivors have not been well documented. We investigated the vascular responses to exercise in cancer survivors previously
treated with adjuvant cancer therapies.
Methods and Results-—Peripheral vascular responses were investigated in 11 cancer survivors previously treated with adjuvant
cancer therapies (age 586 years, 3430 months from diagnosis) and 9 healthy controls group matched for age, sex, and
maximal voluntary contraction. A dynamic handgrip exercise test at 20% maximal voluntary contraction was performed with
simultaneous measurements of forearm blood ﬂow and mean arterial pressure. Forearm vascular conductance was calculated from
forearm blood ﬂow and mean arterial pressure. Left ventricular ejection time index (LVETi) was derived from the arterial pressure
wave form. Forearm blood ﬂow was attenuated in cancer therapies compared to control at 20% maximal voluntary contraction
(189.853.8 vs 247.980.3 mLmin1, respectively). Forearm vascular conductance was not different between groups at rest or
during exercise. Mean arterial pressure response to exercise was attenuated in cancer therapies compared to controls
(107.810.8 vs 119.216.2 mm Hg). LEVTi was lower in cancer therapies compared to controls.
Conclusions-—These data suggest an attenuated exercise blood ﬂow response in cancer survivors 34 months following adjuvant
cancer therapy that may be attributed to an attenuated increase in mean arterial pressure. ( J Am Heart Assoc. 2017;6:e004784.
DOI: 10.1161/JAHA.116.004784.)
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C hemotherapy or a combination of chemotherapy andradiation are frequently used to treat several types of
cancer. Cancer survivors treated with these anticancer
therapies have an increased survival rate,1 but are often at
an increased risk for cardiovascular disease, with myocardial
injury consistently reported as a long-term treatment side
effect (for review, see Khouri et al2). However, the cardiovas-
cular toxicity observed within the myocardium may also occur
within the peripheral vasculature, given that the mean
vascular age of cancer survivors has been reported to be
8 years greater than chronological age, suggesting that a
degree of vascular dysfunction may be present within the
vasculature of some cancer survivors.3 Despite the increased
risk of cardiovascular disease, established cardiac toxicity,
and advanced vascular aging in many cancer survivors, the
effects of chemotherapy and radiation on vascular function
remains poorly understood, particularly in the years following
treatment.4
To date, the effects of chemotherapy and radiation on
vascular health have primarily been studied in childhood
cancer survivors or following a single treatment session.5–7
Chow et al observed a decreased brachial artery
ﬂow-mediated dilation (FMD), a measurement of endothelial-
dependent dilation, 20 months following anthracycline-
based chemotherapy.5 Similarly, Vaughn et al demonstrated
a decreased FMD in long-term survivors of testicular cancer.
These decreases in vascular function, which are associ-
ated with increased mortality and morbidity, can lead to
decreases in blood ﬂow and increases in arterial stiffness.8 As
such, in subjects receiving anthracycline chemotherapy,
From the Department of Health and Exercise Science, The University of
Oklahoma, Norman, OK (K.D.D., A.K.E., L.K.R., M.B., R.H., J.C., C.B., M.G.B.,
C.J.A.); Department of Kinesiology, Kansas State University, Manhattan, KS
(K.D.D., J.C., C.J.A.).
Correspondence to: Carl J. Ade, PhD, Department of Kinesiology, Kansas
State University, 920 Denison Ave, 1A Natatorium, Manhattan, KS 66506.
E-mail: cade@ksu.edu
Received September 29, 2016; accepted January 5, 2017.
ª 2017 The Authors. Published on behalf of the American Heart Association,
Inc., by Wiley Blackwell. This is an open access article under the terms of the
Creative Commons Attribution License, which permits use, distribution and
reproduction in any medium, provided the original work is properly cited.
DOI: 10.1161/JAHA.116.004784 Journal of the American Heart Association 1
ORIGINAL RESEARCH
 by guest on A
ugust 15, 2017
http://jaha.ahajournals.org/
D
ow
nloaded from
 
Chaosuwannaki et al, Miza-Stec et al, and Draft et al inde-
pendently demonstrated signiﬁcant increases in aortic stiff-
ness 4 to 6 months following treatment, which, attributed to
increase in vascular resistance, can decrease peripheral blood
ﬂow.9–12
Decreases in limb blood ﬂow and vascular conductance
have been shown to have key implications in both function
and disease risk in humans.13,14 Whereas whole-body
exercise stress is commonly used in the clinical setting to
evaluate integrated cardiorespiratory function, it is limited by
an inability to investigate key peripheral vascular responses.
Handgrip exercise is a common exercise model that utilizes
a small muscle mass and allows for direct noninvasive
investigation of blood ﬂow control.15,16 Importantly,
decreases in vascular function and the control of blood
ﬂow during exercise will decrease exercise capacity, which is
inversely related to mortality rate in healthy individuals17,18
and may play a role in the development and persistence of
cancer-related fatigue.19 Given that little is known to date
about the peripheral vascular control of blood ﬂow in cancer
survivors, the purpose of the present study was to
investigate vascular responses to exercise in cancer sur-
vivors previously treated with adjuvant cancer therapies. It
was hypothesized that in relation to healthy cancer-free
controls, cancer survivors previously treated with chemother-
apy or a combination of chemotherapy and radiation would
have a signiﬁcantly decreased limb blood ﬂow during
submaximal dynamic forearm exercise. To test these
hypotheses, exercise blood ﬂow was measured by two-
dimensional (2D) Doppler ultrasound during dynamic hand-
grip exercise. This modality of exercise was utilized because
it allows for controlled workloads and stable noninvasive
vascular measurements compared to traditional lower-limb
treadmill or cycling exercise. As such, this modality of
exercise has previously been used to evaluate exercise blood
ﬂow responses in aged and clinical populations.15,16
Methods
Subjects
This study utilized a cross-sectional, case-control study
design, with 11 participants recruited to a cancer survivor
group (10 women) and 9 participants recruited to a control
group (8 women). Control participants were selected if their
age and maximal voluntary contraction (MVC) were within 2.5
SDs of the means for the cancer survivor group. All women
were postmenopausal. History of chemotherapy and radiation
treatment history, date of last treatment, and conﬁrmation of
≥12 months from cancer diagnosis was obtained from the
treating oncologists or family practitioner for all cancer
survivor participants. Individuals in the control group were
recruited from local advertisements. Exclusion criteria
included previous diagnosis with diabetes mellitus, cystic
ﬁbrosis, cardiopulmonary disease, chronic obstructive pul-
monary disease, asthma, lung disease, or microvascular/
peripheral artery disease or were currently anemic as
determined by health history questionnaire. Subjects were
free of signs or symptoms indicating the presence of
pulmonary, metabolic, or cardiovascular disease. Individuals
with uncontrolled hypertension (systolic blood pressure [SBP],
>160 mm Hg), or currently smoking were excluded from the
study. None of the participants were currently taking
prescription blood pressure medication or other prescribed
medication. Current level of physical activity was determined
using the International Physical Activity Questionnaire.20
Informed consent was obtained from all individuals included
in the study according to the University of Oklahoma
(Norman, OK) Institutional Review Board for Research Involv-
ing Human Subjects requirements. All testing was conducted
in a temperature-controlled laboratory (21–23°C) after a 4-
hour fast and having refrained from strenuous exercise,
alcohol, and caffeine for at least 12 hours.
Experimental Protocol
MVC was measured in triplicate in the right arm with a
handgrip dynamometer (EH101; Camry, South El Monte, CA)
and highest value recorded. Following a 10-minute rest supine
period, single-arm dynamic handgrip exercise was performed
in the right arm on a custom-built handgrip ergometer with
the arm abducted to 80° at heart level. Each participant
performed a workload equivalent to 20% MVC for 4 minutes
to ensure a steady state was achieved. Given that forearm
blood ﬂow (FBF) is related to the absolute workload
performed21 and potential arterial occlusion occurs with
≥30% MVC workloads,22 cancer survivor and control partic-
ipants were group matched for MVC so that both absolute and
relative exercise workloads would be similar between groups.
Each workload was achieved by lifting the prescribed weight
3 cm over a pulley at a duty cycle of 1 second contraction
and 2 seconds relaxation, with a metronome used to ensure
correct timing. To minimize the potential risk of external
stimuli altering cardiovascular responses, participants were
asked to refrain from talking and to remain as still as possible
while the experimental measurements were performed
throughout baseline and exercise study periods.
Experimental Measurements
Resting mean arterial blood pressure (MAP) was measured
from the average of 3 brachial artery pressure recordings
following a 10-minute rest period in the supine position
(Omron 10 Plus Series; Omron Healthcare, Hoofddorp, The
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Netherlands). Baseline and handgrip exercise beat-by-beat
MAP was continuously measured by calibrated ﬁnger photo-
plethysmography (Finometer Pro; Finapress Medical Systems,
Amsterdam, The Netherlands) and averaged over the last
30 seconds of exercise. This system has previously been used
to evaluate blood pressure responses to handgrip exercise in
clinical populations.23 In all instances, arterial pressure
recordings were performed at heart level. In addition, the
data for each beat were processed to obtain measurements of
left ventricular ejection time (LVET), which was corrected for
changes in heart rate to determine LVET index (men, LVETi
1.79heart rate+LVET; women, LVETi 1.69heart rate+LVET).24
Arterial pressure wave-form–derived measurements of LVETi
can be affected by changes in ventricular performance and
vascular tone (eg, elastiance, compliance, and stiffness),
which may lead to over- or underestimation of measurements
obtained at the left ventricle and therefore should be
interpreted only as an estimate of ventricular function.
A 2D and Doppler ultrasound system (Logiq S8; GE Medical
Systems, Milwaukee, WI) with a linear array transducer
operated at an image frequency of 10.0 MHz was used to
simultaneously measure the brachial artery diameter and
blood velocities. Doppler velocity measurements were made
in pulse-wave mode at a Doppler frequency of 4.0 MHz and
corrected for an angle of insonation less than 60 degrees.
During handgrip exercise, all ultrasound measurements were
made 5 to 10 cm above the antecubital fossa, mid-
way between the antecubital and axillary regions, medial to
the m. biceps brachii. Time-averaged mean velocity values
were measured and averaged over a 3-second interval on the
ultrasound system using the manufacturer’s onscreen
software. Brachial artery diameter was calculated at 15 Hz
and averaged into 3-second bins using an automated
edge-detection software (Medical Imaging Applications,
Coralville, IA).
During the fourth minute of the handgrip exercise,
workload 2D ultrasound images and Doppler velocity wave-
forms were recorded with the last 30 seconds used for data
analysis. Time-aligned artery diameter and mean velocity were
used to calculate FBF [forearm blood ﬂow (mLmin1)=mean
velocity9p9vessel radius2960]. Forearm vascular conduc-
tance (FVC) [mLmin1(100 mm Hg)1] was calculated as
the ratio of FBF to the time-aligned MAP [forearm vascular
conductance (mLmin1(100 mm Hg)1)=(forearm blood
ﬂow/mean arterial pressure)9100].
Statistical Analysis
All statistical tests were conducted using a commercial
statistical software package (SigmaPlot/SigmaStat 12.5;
Systat Software, Point Richmond, CA). Subject characteristics
were analyzed with parametric or nonparametric statistics
following a Shapiro–Wilk test of normality. Cardiovascular
responses with exercise were analyzed by a 2-factor,
repeated-measures ANOVA with Student–Newman–Keuls
post-hoc analyzes. Given the large post-treatment time frame
within the cancer survivor group, linear regression analysis
was used to evaluate the relationship between months post-
treatment and FBF response. Statistical signiﬁcance was
declared when P<0.05. All data are presented as meanSD,
unless otherwise stated.
Results
Individual cancer survivor characteristics of age, sex, months
since last date of treatment, chemotherapy drugs used, and
radiation exposure are presented in Table 1. Table 2
describes the baseline characteristics of each group. There
were no signiﬁcant differences in age, height, weight, and
body mass index (BMI) between cancer survivor and control
participants. Resting SBP, diastolic blood pressure (DBP), and
MAP were also not different between groups (P<0.05).
Forearm MVC and the absolute workload performed at 20%
MVC were not different between groups. Thus, participants
were performing both the same absolute and relative exercise
workloads. In the cancer survivor group, 9 (82%) individuals
were classiﬁed as inactive and 2 (18%) as minimally active
individuals. The control group was composed of 6 (67%)
inactive and 3 (33%) minimally active individuals.
Supine, resting FBF was not different between cancer
survivors and controls (survivors, 63.741.3; controls,
63.031.2 mLmin1; P=0.97). During handgrip exercise at
20% MVC, FBF was signiﬁcantly lower in the cancer survivors
compared to controls (Figure 1A). Figure 2 illustrates FBF
response in a representative cancer survivor and control
participant. Note that FBF is lower in the cancer survivor
despite performing a similar absolute workload. The associ-
ation between the number of months post-treatment and FBF
response was not statistically signiﬁcant (r=0.5; SEE, 42.77;
P=0.13). FVC was not different between cancer survivors and
controls during the exercise trial (P=0.15; Figure 1B). MAP
was signiﬁcantly decreased in the cancer survivors during
exercise compared to the control group (Figure 1C). In
addition, the estimate of LVETi from the arterial pulse wave
was signiﬁcantly lower in the cancer survivors compared to
controls at rest and during the exercise trail (Figure 3).
Discussion
This study has provided new insight into the peripheral
cardiovascular responses to dynamic handgrip exercise in
long-term cancer survivors previously treated with adjuvant
cancer therapies. First, FBF was attenuated in the cancer
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survivors during moderate-intensity handgrip exercise, but not
FVC. Second, in this group of cancer survivors, arterial
pressure response to exercise was attenuated, which may
have contributed to the attenuated response in FBF during
exercise observed in cancer survivors. Taken together, these
reveal that a cancer survival-related attenuation of forearm
muscle blood ﬂow during exercise may not be a consequence
of differences in vascular conductance, but may be related to
alterations in blood pressure control.
The present ﬁndings indicate that the steady-state FBF
response in the cancer survivors is attenuated during
moderate-intensity handgrip exercise (Figure 1A). This differ-
ence was not attributed to differences in the absolute
workloads performed by each group given that the groups
were matched for MVC so that both the same absolute and
relative exercise workloads were performed. Moreover, as can
be seen in Figure 2, a representative cancer survivor had an
attenuated FBF response compared to a control participant
matched for age, sex, and with an identical MVC, which
reﬂects the mean responses illustrated in Figure 1. Further-
more, we believe the differences observed between groups is
attributed to an reduced blood ﬂow response in the cancer
survivors, not an increased response in our controls, given
that our steady-state blood ﬂow and vascular conductance
values reported for the present study’s control participants is
similar to that reported for healthy aging.16
Our investigation into the underlying factors dictating the
observed decrease in FBF in the cancer survivors revealed
that FVC was not different compared to healthy controls. The
unaltered vascular conductance observed in the cancer
survivors is somewhat at odds with some reports of
cardiovascular function in the weeks following exposure to
cancer therapies. Several studies have examined the effects
of chemotherapy treatments on cardiovascular health25 and
resting cardiac2,26 and peripheral vascular4 function. To date,
several investigations have demonstrated increases in arterial
stiffness within a few weeks following anthracycline
chemotherapy compared to age-matched controls.10–12 Sim-
ilarly, acute exposure to chemotherapy reduces endothelium-
dependent vasodilation.6 Previous studies in testicular cancer
survivors and childhood survivors of leukemia suggest that
endothelium-dependent dilation is decreased on the order of
50% to 75% compared control populations.5,27 In contrast to
these studies, Jones et al reported no difference in endothe-
lium-dependent FMD in adult breast cancer survivors
20 months post-treatment compared to healthy controls.28
During exercise, the increase in FVC in the active arm
occurs through the integration of mechanical factors (ie,
muscle pump) and locally derived endothelial and metabolic
substances.29 There is limited evidence that acute exposure
to radiation or chemotherapy negatively impacts these
factors. Several studies report altered smooth muscle sensi-
tivity to vasoactive substances, including nitric oxide, follow-
ing radiation exposure30,31 and nitric oxide bioavailability may
also be decreased following radiation as a consequence of an
increased oxidative stress.31 Similarly, Duquaine et al report
signiﬁcantly decreased nitrite and nitrate concentrations,
which is an indirect index of nitric oxide production, in
patients after a single dose of chemotherapy.6 Endothelial
injury has also been reported following exposure to doxoru-
bicin chemotherapy in organ culture and animal models.32,33
In the initial months following anthracycline chemotherapy in
pediatric cancer patients, Chow et al observed a decreased
brachial artery endothelium-dependent vasodilation.5
Table 1. Cancer Survivor Treatment Characteristics
ID No. Age (y) Sex Cancer Type
Months
Post-Treatment Chemotherapy Treatment Radiation Treatment
1 55 F Breast cancer 41 Cytoxan+taxol Yes
2 54 F Breast cancer 35 Adriamyacin+cytoxan+ taxotere+abraxane Yes
3 59 F Breast cancer 121 Taxotere+neupogen No
4 56 F Breast cancer 40 Herceptin+taxotere+carboplatin+fermara No
5 59 M Lymphoma 31 Cytoxan+adriamycin+vincristine+etoposide
prednisone+ifosamide+caroplatin
Yes
6 52 F Breast cancer 36 Taxotere+cytoxan Yes
7 67 F Breast cancer 22 Taxotere+cytoxan+neulasta No
8 69 F Breast cancer 12 Arimidex+aromasin Yes
9 52 F Breast cancer 13 Adriamycin+cytoxan+taxol Yes
10 52 F Breast cancer 9 Adriamycin+cytoxan+methotrexate+fluorouracil
+tamoxifen+taxotere+perjeta+herceptin
+faslodex+arimidex
Yes
11 62 F Breast cancer 21 Tamoxifen Yes
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Similarly, in women survivors of breast cancer, Beckman et al
observed a decrease endothelium-dependent vasodilation in
arteries directly exposed to external-beam radiation therapy
compared to healthy women.34 However, no endothelial
dysfunction was observed in the nonirradiated arteries of the
same women, suggesting that the negative cardiovascular
effects of radiation occur only in exposed regions.
The increase in FVC above baseline during exercise in the
cancer survivors of the present study could be taken to
suggest that the observed decreases in endothelial function
following acute radiation and chemotherapy in other studies
does not persist long term. This conclusion is supported by
the work of Jones et al and Ederer et al, who demonstrated
no difference in brachial artery endothelium-dependent FMD
in cancer survivors compared to healthy controls.28,35 Given
the potential role several factors may play in mediating
changes in vascular conductance during dynamic exercise,
future investigations will need to determine the relative roles
factors like nitric oxide and prostacyclin have during exercise
in cancer survivors. Additional investigations will also be
required to determine the role vasodilator pathways, partic-
ularly those related to endothelial function, have in mediating
blood ﬂow during heavy and severe exercise intensities.
Limb blood ﬂow during dynamic exercise is dictated not
only by local increases in vascular conductance, but also by
increases in perfusion pressure through increases in MAP. This
increase in MAP is coordinated by integration of adjustments
in cardiac output, the exercise pressor reﬂex, arterial barore-
ﬂex, and central command.36 Of interest in the present study is
the observed difference in MAP during exercise in cancer
survivors compared to healthy controls. Evaluation of the
blood pressor responses to handgrip exercise in human clinical
and aging populations compared to healthy young controls
regularly utilizes relative exercise intensities.37 However, it is
important to recognize that the MAP response to exercise is
workload and muscle mass dependent.38 Therefore, our goal
was to match the control participants by both age and MVC to
the cancer survivor group, which resulted in an absolute
workload performed by each group that was not statistically
different. Therefore, other factors may have played a key role
in the attenuated MAP response observed in the cancer
survivors compared to healthy controls.
Regarding possible mechanism, decreases in cardiac
output may have contributed to the decreased FBF and
MAP response in the cancer survivor group. Whereas handgrip
exercise only requires a fraction of maximal cardiac output, a
signiﬁcant relationship exists between cardiac output and
limb blood ﬂow at rest.39 In clinical cardio-oncology practice,
an asymptomatic decrease in left ventricular ejection fraction
(LVEF) is the most commonly observed form of cardiotoxic-
ity.40 LVEF deterioration has been shown to occur in cancer
survivors within the ﬁrst year of exposure to chemotherapy
Figure 1. Forearm blood ﬂow (A), forearm vascular
conductance (B), andmean arterial pressure (C) responses
during dynamic forearm exercise at 20% maximal volun-
tary contraction (MVC). Forearm blood ﬂow response was
signiﬁcantly decreased in cancer survivors compared to
controls. Mean arterial pressure response was lower in
cancer survivors during exercise compared to controls,
but not at rest. *P<0.05 versus control. MeanSE.
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treatment and can continue to decrease in the months
following chemotherapy treatment. In addition, several
reports have demonstrated a decreased LVEF during exercise
following cancer treatment with doxorubicin.41,42 During
exercise, increases in cardiac output are achieved, in part,
through increase in stroke volume attributed to increases in
ventricular preload and contractility. Therefore, if LVEF was
reduced in the cancer survivors, it is possible that it played a
role in limiting the increase in MAP and subsequent limb
perfusion pressure and blood ﬂow. In the present study, direct
measurements of cardiac function were not made and limit
our ability to mechanistically determine the factors contribut-
ing the decreased limb blood ﬂow in the cancer survivor
group. However, estimates of LVETi derived from the arterial
pressure waveform were signiﬁcantly decreased in the cancer
survivors compared to controls. These data suggest that
decreases in left ventricular performance may have con-
tributed to the decreased FBF observed in the cancer
survivors. However, this should be interpreted with caution
given that estimates of LEVT from peripheral arteries may not
completely reﬂect what occurs at the left ventricle. Future
investigations performing simultaneous cardiac and vascular
evaluations during exercise stress are required to fully
address this issue.
The increase in arterial pressure during dynamic exercise is
also achieved by adjustments within the autonomic nervous
system through the integration of central command, arterial
baroreﬂex, and the exercise pressor reﬂex.43 Several studies
to date have pointed to the presence of chemotherapy-
induced peripheral neuropathy in cancer patients receiving
adjuvant therapy, which often does not completely recover
(for review, see Quasthoff and Hartung44). Given the integral
role of the type III and IV afferent arms of the exercise pressor
reﬂex during exercise in mediating the mechanically and
chemically evoked increases in MAP,43 it is possible that
some form of peripheral neuropathy still existed in the
present study’s cancer group. In addition, an attenuated
increase sympathetic nerve activity subsequent to a
depressed exercise pressor reﬂex would have an adverse
impact on cardiac function. Peripheral neuropathy is com-
monly assessed in cancer patients using a series of
questionnaires or by clinician grading.45 Unfortunately, an
assessment of peripheral neuropathy was not performed in
the present study and will require further investigation to
determine its role in blood pressure control during exercise.
Implications
In addition to cardiotoxicity and changes in cardiovascular
disease risk, cancer survivors have a decreased exercise
capacity46 and presence of cancer-related fatigue symp-
toms.47,48 Of importance, both have been shown to be related
to mortality rate17,18 and functional outcomes (eg, ability to
return to work).49 Inmany patient populations, like heart failure,
the peripheral blood ﬂow response to exercise is a key
mechanism in determining exercise capacity and could play a
key role in cancer patients.50,51 Although this study did not
evaluate exercise capacity or cancer-related fatigue, it is
reasonable to speculate that changes in peripheral vascular
function may be an underlying factor in the decreased exercise
capacity associated with adjuvant cancer therapies and in
cancer survivors.51 To date, no other studies have investigated
peripheral blood ﬂow responses to exercise in cancer survivors,
Figure 2. Forearm blood ﬂow response to handgrip exercise in
individual cancer survivors and controls (A). Given that control
participants were selected if their age and maximal voluntary
contraction (MVC) were within 2.5 SDs of the means for the
cancer survivor group, a representative female cancer survivor
and control are also presented who were similar in both age and
BMI (B). BMI indicates body mass index.
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and the present ﬁndings suggest that peripheral cardiotoxicity
with cancer treatments should not be overlooked.
Limitations
The strengths of the study include the use of a diverse group
of cancer survivors, which allow the ﬁndings to be generalized
to more than a single chemotherapy drug, radiation exposure,
or cancer type. Similar to the present study, other studies
have also used participants from different cancer populations
when evaluating evidence of cardiovascular disease.11 How-
ever, having a diverse group of cancer populations is a
limitation and does not allow the exact treatment-related
mechanisms to be explained. For instance, it is well estab-
lished that anthracycline chemotherapy drugs negatively
impact long-term cardiovascular health.2 Additionally, the
taxane class of chemotherapy drugs are often associated with
chemotherapy-induced peripheral neuropathy.52 As noted in
Table 1, the cancer survivors in the present study were
treated with various combinations of anthracycline and taxane
class chemotherapies. Whereas certain types of chemother-
apy medications, like anthracycline chemotherapy, are asso-
ciated with adverse cardiac health, there is a paucity of
information regarding the effects of speciﬁc chemotherapies
on peripheral vascular health. Given this, we had no justiﬁ-
cation for examining only 1 type of chemotherapy or cancer at
this time. Therefore, the type of chemotherapy and type of
cancer were not controlled for, but was recorded for each
participant. There are several additional limitations to this
study that need to be addressed. First, the population studied
was predominantly female and therefore does not accurately
represent all cancer survivors.53 Second, the sample size was
modest, but very similar to previous investigations investigat-
ing the effects of healthy aging on the peripheral cardiovas-
cular responses to dynamic handgrip exercise.16,54 The
present study also did not evaluate differences in arterial
stiffness because of a lack of proper equipment at the time of
data collection. The fourth limitation concerns the cross-
sectional design. A longitudinal study design would have been
more robust and may have allowed for a more-mechanistic
evaluation of blood ﬂow and vasodilator responses following
adjuvant cancer treatments. This type of study design would
have minimized the effects of various confounding variables
that may have introduced variability into the present study.
Summary
This is the ﬁrst study, to our knowledge, to quantify and
characterize the impact of previous adjuvant cancer therapy
Figure 3. Left ventricular ejection time index (LVETi) derived
from the arterial pressure waveform during dynamic forearm
exercise at 20% maximal voluntary contraction (MVC). LVETi was
signiﬁcantly decreased in cancer survivors compared to controls.
*P<0.05 versus control. MeanSE.
Table 2. Participant Characteristics
Characteristics Value
Control participants
Sex (M/F) 1/8
Age, y 566
Height, cm 166.76.0
Weight, kg 72.117.7
BMI, kg/m2 25.56.5
MVC, kg 308
Heart rate, bmp 619
SBP, mm Hg 14823
DBP, mm Hg 786.0
Cancer subjects
Sex (M/F) 1/10
Age, yr 586
Height, cm 167.04.5
Weight, kg 79.919.54
BMI, kg/m2 28.66.3
MVC, kg 288
Heart rate, bpm 676
SBP, mm Hg 15022
DBP, mm Hg 7611
Values expressed as meansSD. BMI indicates body mass index; bpm, beats per minute;
DBP, diastolic blood pressure; MVC, maximal voluntary contraction; SBP, systolic blood
pressure.
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in cancer survivors on peripheral vascular responses to
dynamic exercise. During dynamic handgrip exercise in cancer
survivors previously treated with adjuvant cancer therapy, an
attenuated blood ﬂow and arterial pressure responses were
observed compared to controls. In contrast, FVC during
exercise was not inﬂuenced by cancer survival. These ﬁndings
highlight the contribution the decreased arterial pressure
response to exercise may have on attenuated blood ﬂow
response in our cancer survivors. The mechanistic reasons for
these ﬁndings and the functional consequences can only be
speculated on at this point, but may, in total, contribute to the
altered cardiorespiratory function previously reported in this
population.46
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